Cadent Capital Advisors LLC Boosts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Cadent Capital Advisors LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 72,160 shares of the company’s stock after buying an additional 1,060 shares during the period. Cadent Capital Advisors LLC’s holdings in Hims & Hers Health were worth $1,745,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HIMS. GAMMA Investing LLC boosted its holdings in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC lifted its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Quarry LP boosted its stake in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares during the last quarter. Finally, Amalgamated Bank grew its holdings in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on HIMS. Needham & Company LLC lifted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Morgan Stanley assumed coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler boosted their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Stock Performance

NYSE:HIMS traded up $0.09 during mid-day trading on Monday, hitting $25.50. 6,863,560 shares of the company’s stock traded hands, compared to its average volume of 9,132,327. The firm’s 50 day simple moving average is $27.21 and its 200 day simple moving average is $21.64. The company has a market cap of $5.57 billion, a PE ratio of 57.96 and a beta of 1.31. Hims & Hers Health, Inc. has a 1 year low of $8.14 and a 1 year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This represents a 1.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the sale, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. This trade represents a 3.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,063,707 shares of company stock valued at $28,696,798 in the last three months. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.